Managing Therapeutic Competition in Patients with Heart Failure, Lower Urinary Tract Symptoms and Incontinence by Cara Tannenbaum & Kristina Johnell
THERAPY IN PRACTICE
Managing Therapeutic Competition in Patients with Heart
Failure, Lower Urinary Tract Symptoms and Incontinence
Cara Tannenbaum • Kristina Johnell
Published online: 20 December 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Up to 50 % of heart failure patients suffer from
lower urinary tract symptoms. Urinary incontinence has
been associated with worse functional status in patients
with heart failure, occurring three times more frequently in
patients with New York Heart Association Class III and IV
symptoms compared with those with milder disease. The
association between heart failure and urinary symptoms
may be directly attributable to worsening heart failure
pathophysiology; however, medications used to treat heart
failure may also indirectly provoke or exacerbate urinary
symptoms. This type of drug–disease interaction, in which
the treatment for heart failure precipitates incontinence,
and removal of medications to relieve incontinence wors-
ens heart failure, can be termed therapeutic competition.
The mechanisms by which heart failure medication such as
diuretics, angiotensin-converting enzyme (ACE) inhibitors
and b-blockers aggravate lower urinary tract symptoms are
discussed. Initiation of a prescribing cascade, whereby
antimuscarinic agents or b3-agonists are added to treat
symptoms of urinary urgency and incontinence, is best
avoided. Recommendations and practical tips are provided
that outline more judicious management of heart failure
patients with lower urinary tract symptoms. Compelling
strategies to improve urinary outcomes include titrating
diuretics, switching ACE inhibitors, treating lower urinary
tract infections, appropriate fluid management, daily
weighing, and uptake of pelvic floor muscle exercises.
1 Introduction
While medications are essential for palliating symptoms
and improving survival, prescription of additional medi-
cations for one condition may commonly precipitate or
worsen other co-morbidities. Therapeutic competition is
a type of bidirectional drug–disease interaction that
occurs when treatment for the first condition adversely
impacts the second, and subsequent treatment of the
second condition exacerbates the first [1]. An important
example of therapeutic competition is between heart
failure treatment and urinary incontinence, a common
geriatric syndrome. Urinary incontinence reduces dignity,
autonomy and mood in later life and should be pre-
vented at all costs [2]. This article reviews the mecha-
nisms and possible solutions for managing therapeutic
competition between heart failure and lower urinary tract
symptoms in older adults.
Heart failure affects 1–3 % of the general population [3,
4]. The prevalence of lower urinary tract symptoms is
much higher, reported to occur in over 50 % of men and
women [5]. Urinary frequency, urinary urgency, nocturia
and urinary incontinence are among the most common
lower urinary tract symptoms [5, 6]. Urinary incontinence
can be subclassified into stress, urgency, and mixed or
functional incontinence. Involuntary urine leakage that
occurs with coughing, laughing or sneezing is called stress
incontinence and is caused by intravesicular pressures that
exceed urethral closing pressures. Urgency incontinence is
associated with a sudden, compelling urge to void, and
often coexists with other symptoms of overactive bladder
such as frequency, urgency and nocturia. Functional
incontinence has typically been described in frail older
adults with mobility or cognitive impairment, and refers to
the inability to reach the toilet in time to void [7].
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Studies indicate that 35–50 % of heart failure patients
suffer from urinary incontinence [8–10]. Urinary inconti-
nence is associated with reduced functional capacity in
older adults with heart failure [11]. Although urinary
symptoms may antedate the diagnosis of heart failure,
urinary urgency with or without incontinence is found to be
2.9 times (95 % CI 1.3–6.3) more prevalent in patients with
New York Heart Association Class III or Class IV heart
failure compared with Class I or Class II. This suggests that
worsening heart failure either provokes or exacerbates
urinary symptoms [12]. A direct association between heart
failure pathophysiology and bladder dysfunction may
explain this relationship; or perhaps other co-morbidities
such as diabetes mellitus or renal failure play a role [13–
15]. Alternatively, medications such as diuretics, angio-
tensin-converting enzyme (ACE) inhibitors and b-blockers,
which are frequently prescribed for patients with heart
failure, may indirectly be at cause.
Mr. S. is an 84-year-old man recently admitted to
hospital with decompensated heart failure. He had an
ST-elevation myocardial infarction 10 years ago and
again last year. Prior to his admission he was active
and well. Upon discharge his medications included
Monopril 10 mg orally daily, furosemide 40 mg
orally twice daily, aldactone 25 mg orally twice
daily, bisoprolol 5 mg orally daily, atorvastatin
20 mg orally daily, metformin 850 mg orally twice
daily, acetylsalicylic acid (ASA, aspirin) 80 mg
orally daily, pantoprazole 40 mg orally daily, and
oxazepam 15 mg orally every night. Three months
post-discharge he has become increasingly depressed,
and is no longer enjoying activities such as golfing
with his friends. He experiences urinary urgency
eight to ten times per day, four times nightly, and
regularly leaks urine on the way to the toilet. He is
reluctant to go out for fear of leakage and odor. His
self-esteem is low, he does not want to wear protec-
tive undergarments and he is rapidly losing the will to
live.
2 Mechanisms Underlying the Risk of Lower Urinary
Tract Symptoms in Heart Failure Patients
Direct precipitation of lower urinary tract symptoms during
heart failure can be due to compensatory secretion of
natriuretic peptides [16]. Natriuretic peptides play an
important role in the body’s regulation of intravascular
volume by promoting excretion of sodium and elimination
of bodily fluid. A number of natriuretic peptides have been
identified: atrial natriuretic peptide, urodilantin, brain
natriuretic peptide (BNP), C-type natriuretic peptide and
Dendroaspis natriuretic peptide [16]. BNP has been widely
studied in relation to cardiac load, with levels typically
rising and falling in association with the severity of heart
failure symptoms. Released from ventricular cardiomyo-
cytes in response to an increase in ventricular wall tension,
BNP has been shown to fluctuate in parallel with hemo-
dynamic measures such as left ventricular end diastolic
pressure. Binding of BNP to the natriuretic peptide A
receptor stimulates a signaling cascade that results in
natriuresis and inhibition of renin and aldosterone. Both
European and North American heart failure guidelines
recognize value in measuring BNP levels as a diagnostic
and prognostic biomarker of heart failure in patients with
dyspnea [17, 18]. High BNP levels have been indepen-
dently associated with the presence and severity of noc-
turnal voiding, as well as nocturnal polyuria in elderly
patients [19]. Redistribution and elimination of fluid from
peripheral or pulmonary edema further contribute to uri-
nary frequency and excessive diuresis, especially at night
when peripheral edema is resorbed in the supine position.
Chronic heart failure patients experience fatigue and
may also become deconditioned due to dyspnea-related
activity restriction. In patients with New York Heart
Association class III–IV symptoms, reduced functional
capacity and decreased mobility are important risk factors
for urinary incontinence, as both impede the ability to
reach the toilet in a timely manner during episodes of
urinary urgency [11]. Predisposing risk factors for lower
urinary tract symptoms, such as pelvic floor muscle
weakness, obesity, or consumption of caffeinated bever-
ages, may synergistically augment the risk of incontinence
in the presence of heart failure pathology. Exacerbation of
pre-existing symptoms of incontinence can also occur.
Indirect effects of both acute and chronic heart failure
on the lower urinary tract may be mediated by prescription
of medications for both tertiary prevention and symptom-
atic relief. Drug therapy in heart failure is essential for
slowing disease progression and for improvement of
symptoms and survival [20]. However, as a part of their
modes of action or as side effects, many of these medica-
tions can iatrogenically contribute to urinary frequency,
urgency, nocturia or incontinence [8, 21–23].
3 Heart Failure Medications that Precipitate
or Worsen Urinary Incontinence
Although diuretics are typically used to relieve congestion,
and ACE inhibitors and angiotensin receptor blockers
(ARBs) improve survival, these classes of drugs have been
suggested to accelerate and worsen urinary symptoms in
the presence of heart failure. b-blockers are also frequently
prescribed for heart failure patients and can potentially
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have an impact on the lower urinary tract. Because heart
failure, urinary problems and use of these medications are
common in old age, this is above all a geriatric
complication.
3.1 Diuretics
Diuretics are part of the first-line treatment for symptom-
atic relief of heart failure. These drugs increase sodium
urinary excretion and decrease physical signs of fluid
retention [24]. Clinical trials have shown that the use of
diuretics leads to a reduction in venous pressure, edema
and body weight [25], with the consequence of providing
symptomatic relief and improvement of quality of life for
patients with heart failure and preserved systolic function
[26]. These symptomatic benefits occur more rapidly with
diuretics than for other heart failure drugs. The long-term
effects include improvement in cardiac function and
exercise tolerance, with positive effects on morbidity and
mortality [24].
Nonetheless, the desired actions of diuretics in heart
failure—increased urine sodium excretion and volume of
urine—can also cause urinary frequency, urgency and
incontinence [27]. There are, however, differences between
loop diuretics and non-loop diuretics, where loop diuretics
have been more often associated with urinary tract symp-
toms. Use of loop diuretics has been related to increased
urinary frequency and urgency [28], whereas non-loop
diuretics have not.
Studies on incontinence are conflicting. Cross-sectional
analyses have suggested that diuretics may be implicated in
causing incontinence [29, 30], whereas longitudinal studies
have not confirmed this finding [31, 32].
The later stages of heart failure are characterized by
fluid overload and a chronic state of overhydration. At this
stage, even high doses of loop diuretics might prove inef-
fective, a phenomenon known as diuretic resistance [33,
34]. An important mechanism behind diuretic resistance is
functional adaptation of the distal tubule after chronic
exposure to loop diuretics. One way to overcome the
problem is to add diuretics acting on different sites of the
nephron [34]. Typically, a thiazide-type diuretic, hydral-
azine, or other potassium-sparing or mineralocorticoid
diuretics are combined with loop diuretic therapy to attain
diuretic synergy. This is common clinical practice,
although there is a lack of high-level evidence for use of
this combination. While the combination therapy can prove
effective for resistant patients, it can also cause hypoka-
lemia and worsening renal function [33]. Additionally, the
synergistic effects of combination therapy may cause
heavy diuresis, potentially aggravating urinary frequency
and urgency in late-stage heart failure patients. However,
this has, to our knowledge, not yet been investigated.
3.2 Angiotensin-Converting Enzyme (ACE) Inhibitors
ACE inhibitors are standard therapy in heart failure
patients with symptomatic left ventricular systolic dys-
function. They have been shown to reduce morbidity and
mortality in clinical trials; however, there is less evidence
for treatment with ACE inhibitors in all patients with heart
failure and in those with preserved ejection fraction [35].
Although ACE inhibitors are generally well tolerated, they
are associated with a persistent cough probably caused by
increased levels of bradykinin and tachykinin. The ACE
inhibitor-induced cough is characterized by being dry, non-
productive and worse at night [36], and occurs in 5–35 %
of patients taking ACE inhibitors [37]. This cough can
produce or exacerbate stress incontinence by increasing
urethral pressure. A number of case reports have described
cough-induced stress incontinence upon initiation of an
ACE inhibitor, which remits upon discontinuation [38, 39].
One case series reported a 10 % incidence of severe drug-
induced stress incontinence in diabetic post-menopausal
women initiating ACE inhibitors [40].
3.3 b-Blockers
b-Blockers have been extensively studied in the treatment
of heart failure, and are standard treatment for improve-
ment of clinical outcomes of heart failure patients [41].
There is a chronic activation of the sympathetic nervous
system in heart failure in an attempt to restore cardiac
output. This is a compensatory mechanism that provides
inotropic support to the failing heart by increasing stroke
volume and peripheral vasoconstriction. However, these
measures eventually accelerate disease progression and
negatively affect survival [42]. b-Blockers affect heart
failure by inhibiting sympathetic nervous system activa-
tion. This effect has been shown to reduce morbidity and
mortality in several clinical trials [20]. In the context of
incontinence, emerging evidence suggests that b-blockers
may increase bladder contractility and provoke symptoms
of urinary urgency [30, 43]. The effects of b-blockers on
the risk of incontinence are, however, inconsistent [44, 45]
and require further investigation.
4 Overactive Bladder Medications that Precipitate
or Worsen Heart Failure
Avoidance of prescribing cascades in the elderly is a key
tenet of pharmacologic management in this population.
Increased urinary frequency and urgency due to diuretic
dose escalation during acute heart failure episodes may
motivate patients to consult for incident symptoms of
overactive bladder. The overactive bladder syndrome
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comprises symptoms of urinary urgency, with or without
urinary frequency and nocturia, in the presence or absence
of urgency urinary incontinence [6]. Consultation for
overactive bladder may lead to prescription of one of two
oral pharmaceutical classes of medication for the treatment
of overactive bladder symptoms. Both antimuscarinic
agents and b3-adrenergic agonists have proven efficacy for
reducing symptoms of urinary frequency, urgency and
incontinence [46, 47]. If a proper medication history is not
ascertained, and neither the patient nor the consultant
makes the link between heart failure medications and uri-
nary symptoms, a prescribing cascade for the treatment of
overactive bladder may ensue.
4.1 Antimuscarinic Agents
Antimuscarinic drugs are the mainstay of treatment for
patients with symptoms of overactive bladder, including
urgency incontinence. Blockade of M2 and M3 receptors in
the bladder detrusor muscle reduces urinary urgency, fre-
quency and urgency incontinence. However, blockade of
muscarinic cholinergic receptors (primarily M2 subtype)
on sinoatrial nodal cells can also potentially increase heart
rate, which is best avoided in patients with heart failure
[48]. Several antimuscarinic agents are approved for the
treatment of overactive bladder syndrome, all with differ-
ent relative affinities for the M2 subtype [48]. QT interval
prolongation and induction of polymorphic ventricular
tachycardia (torsade de pointes) are other theoretical con-
cerns with the use of antimuscarinic agents in heart failure
patients [48]; however, few studies have specifically
investigated whether antimuscarinic agents exert these
effects in the real-life setting. Based on available infor-
mation, any effects that exist appear to be modest and their
clinical relevance unknown. Data suggest that the preva-
lence of cardiovascular co-morbidities is significantly
higher in patients with than without overactive bladder, and
that cardiovascular co-morbidities are found to be more
prevalent in treated versus untreated patients (58.8 vs.
53.7 %; p \ 0.001). The association between antimuscar-
inic agents and cardiovascular adverse events therefore
warrants further investigation [49, 50].
4.2 b3-Adrenoceptor Agonists
The b3-adrenoceptor subtype is dominant in the human
detrusor muscle, and activation of the b3-adrenoceptor
mediates relaxation of the detrusor during the storage phase
of the micturition cycle, improving bladder storage
capacity without impeding bladder voiding [47]. Mira-
begron is a selective b3-adrenoceptor agonist approved for
the treatment of overactive bladder. b3-adrenoceptors are
thought to account for more than 95 % of all b-adrenergic
messenger RNA in the human bladder, and are highly and
preferentially expressed on urinary bladder tissues,
including the urothelium, interstitial cells and detrusor
smooth muscle [47]. Concern about cross-reactivity with
b1- and b2-adrenoceptor subtypes found in the vasculature
and cardiac muscle, as well as direct stimulation of b3-
adrenoceptors in the heart, have raised concern about the
cardiac safety of mirabegron in heart failure patients [51].
A meta-analysis of three randomized clinical trials with
a pool of over 2,760 patients looked at treatment-emergent
adverse effects due to mirabegron [47]. Adverse effects
included hypertension (odds ratio [OR] 0.91, 95 % CI
0.68–1.21) and cardiac arrhythmias (OR 1.67, 95 % CI
0.95–2.92, p = 0.07). These results suggest no obvious
effect of b3-agonists on cardiac function in participants in
these trials. However, interpretation must be made with
caution as the study population was not representative of
elderly patients with multiple morbidities and chronic heart
failure, although many were on b-blockers for the treat-
ment of hypertension. Further research is warranted on the
specific effects of b3-agonists in heart failure patients, as
well as the combined use of b-blockers and b-agonists in
this population.
At Mr. S’s 3-month follow-up visit his depression is
apparent. He is disheveled and talks about constantly
needing to run to the toilet. Screening questions
reveal that he experiences urge incontinence which is
affecting his sense of dignity. Dyspnea on exertion
and orthopnea are absent. Pedal edema is minimal.
His skin turgor is low and he complains of dry mouth.
Urinalysis is negative. His diabetes is well-controlled
but his renal function has worsened. He has started
drinking two bottles of beer in the evening. Mr. S.
does not know why he is taking oxazepam; he says it
was prescribed upon discharge from hospital. He
wants to know if there are medications to take to
control his urine leakage.
5 Management of Therapeutic Competition in Patients
with Heart Failure and Urinary Symptoms
Recommendations and practical tips for the management of
heart failure patients with lower urinary tract symptoms
entail a variety of pharmacological modifications and non-
pharmacological interventions. Figure 1 illustrates differ-
ent therapeutic approaches to patients with stress inconti-
nence, symptoms of urinary frequency and urgency—
including urgency incontinence—and nocturia. A sudden
change in urinary symptoms may signal newly decom-
pensated heart failure or the presence of a urinary tract
infection. These possibilities should be ruled out and
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addressed prior to proceeding with other management
strategies.
5.1 Dose Reduction of Diuretics
Consider reassessing the need and reducing the dose of
diuretics if the patient is otherwise stable. Although com-
plete discontinuation of diuretics can lead to decompen-
sation and relapse [52], many patients are discharged from
hospital after an acute episode with high-dose oral diuret-
ics, equivalent to the intravenous doses that were required
to relieve symptoms upon admission. When acute con-
gestion is cleared, the lowest dose should be used that is
compatible with stable signs and symptoms.
5.2 Substitution of ACE Inhibitors with Angiotensin
Receptor Blockers
ARBs do not inhibit degradation of bradykinin, thought
to be responsible for the ACE inhibitor-induced cough.
ARBs and ACE inhibitors are equal in terms of reduction
of mortality and morbidity in heart failure patients, but
discontinuation due to adverse effects is lower with
ARBs [53]. Therefore, switching to an ARB may be an
alternative to avoid the side effect of coughing and
consequent stress incontinence associated with ACE
inhibitor use [40, 53].
5.3 Rule-Out Reversible Causes of Hospital-Related
Morbidity
(a) Catheter-induced urinary tract infection Patients in
cardiogenic shock or those admitted with acute heart
failure who have difficulty voiding often have a urinary
catheter inserted to monitor urinary output. In-dwelling
catheters provide a nidus for bacterial entry into the
normally sterile lower urinary tract, and increase the
risk of lower urinary tract infection. Exacerbation of
lower urinary tract symptoms including urinary fre-
quency, urgency, nocturia and incontinence post-hos-
pitalization for acute heart failure may indicate the
presence of a new urinary tract infection. Attribution of
symptoms to an increased dose of diuretics may con-
found early diagnosis and treatment, especially as
dysuria and hematuria are less commonly seen as
presenting symptoms and signs of urinary tract infec-
tion in the elderly [54]. Recent guidance from the
American Board of Internal Medicine for adult hospital
medicine recommends that urinary catheters not be
placed, or left in place, to monitor urinary output in
non-critically ill patients, and that weights should be
used instead to track diuresis [55].
(b) Sedative-hypnotic prescriptions Admission to the
intensive care or coronary care unit for treatment of
acute heart failure elicits anxiety among patients as they
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grapple with the impending possibility of mortality.
Anxiety, combined with the need to reduce adrenergic
stimulation and sleeplessness due to the beeps and
disruptions inherent to any high-intensity monitoring
unit, often leads to prescription of a sedative hypnotic
[56]. Evidence suggests that many of these sedative-
hypnotic prescriptions persist upon discharge, with
hospitalization conferring a 2.7-fold greater risk of
incident use than outpatient visits [57]. Medications
that bind to GABAA receptors in the central nervous
system can potentially affect the lower urinary tract
system either directly, by causing relaxation of striated
pelvic floor muscles and/or by interfering with afferent
sensory messages from the bladder, or even indirectly
through an effect on mobility and toileting ability [21,
58]. For this reason, as well as many others, sedative-
hypnotic medications are not recommended in elderly
heart failure patients and should be tapered and
discontinued. Cognitive behavioral therapy is a safer
and equally efficacious alternative to treat insomnia in
the ambulatory care setting [59].
5.4 Fluid Management
Fluid restriction represents a key management strategy in
patients with chronic heart failure. An individualized fluid
management program is recommended for each patient
according to the severity of heart failure, renal function and
other dietary behaviors. Clinically, 1.5–2 litres per day is
recommended for most patients and an intake greater than
2 litres per day is generally discouraged. Patient education
with or without provision of self-management strategies for
fluid management, sodium restriction, daily weighing and
physical conditioning may attenuate urinary problems in
heart failure patients, although formal trials are required to
test the efficacy of this approach [60, 61]. Patients with
recurrent fluid retention who are able to follow instructions
can be taught to adjust their diuretic dose based on
symptoms of dyspnea on exertion and orthopnea and
changes in daily body weight. Use of compression stock-
ings during the day by stable chronic heart failure patients
may help prevent distal leg edema, nocturnal fluid redis-
tribution, and nocturnal urinary frequency and urgency
[62]. The benefit of compression stockings in patients with
decompensated heart failure remains unclear, as the use of
compression stockings has been reported to increase right
atrial and pulmonary pressures [63].
5.5 Dietary Modification
Caffeinated beverages, such as tea, coffee and colas, may
increase urinary urgency and enhance diuresis via the
stimulatory effect of caffeine on the bladder detrusor
muscle [64, 65]. Even though randomized trials of caffeine
reduction in heart failure patients are lacking, epidemiol-
ogic data suggest that caffeine intake equivalent to 2 cups
(234 mg) or greater than 3 cups (392 mg) of coffee per day
is significantly associated with having moderate to severe
urinary incontinence in men (1.72, 95 % 1.18–2.49; and
2.08, 95 % 1.15–3.77, respectively), even when adjusting
for underlying prostate conditions [66]. Studies of women
also reveal that there may be a physiologic link between
high caffeine intake, diuresis, and prevalent and incident
urgency incontinence [67, 68]. Moderate sodium restriction
may also be effective in reducing hospital readmission
rates for chronic heart failure patients [69]. Alcohol con-
sumption has been shown to increase the risk of mortality
in chronic heart failure patients, although the physiologic
mechanism is unclear [70]. Attention to dietary factors
should therefore be recommended as part of any conser-
vative management strategy.
5.6 Pelvic Floor Muscle Exercises
Systematic reviews on the effect of pelvic floor muscle
training on stress urinary incontinence/mixed urinary
incontinence have found that intensive, supervised training
can produce clinically important effects on the reduction of
urine leakage [71]. Pelvic floor muscle exercises, as part of
any conservative management strategy for urgency incon-
tinence, yield equivalent or superior efficacy to pharma-
cological management, with an uncommon risk of adverse
events [72]. Supervision by a trained physiotherapist may
augment the effectiveness of pelvic floor muscle training if
a patient has difficulty identifying their pelvic floor mus-
cles and/or performing the exercises correctly [73].
5.7 Prescription of Medication for Lower Urinary Tract
Symptoms
Although prescription of medication is effective for treat-
ing lower urinary tract symptoms, adherence to antimu-
scarinic agents is poor because of adverse effects such as
dry mouth and constipation [74, 75], and the use of b3-
agonists has not yet been well-studied in heart failure
patients, many of whom are already taking b-blockers. Dry
mouth resulting from the use of antimuscarinic agents can
paradoxically lead to increased fluid consumption and
worsening of heart failure symptoms. Removal of heart
failure medications contributing to lower urinary tract
symptoms is the preferred management approach, rather
than initiating a prescribing cascade and unavoidable
therapeutic competition. Conservative management strate-
gies for the treatment of urinary symptoms, such as
avoidance of caffeinated beverages and regular
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performance of pelvic floor muscle exercises should be
prioritized as first-line treatment.
Upon hearing that his diuretics and sleeping pill may
be contributing to his urinary symptoms, Mr. S. elects
a trial of dose reduction and conservative manage-
ment. He slowly tapers off the benzodiazepine, expe-
riencing withdrawal symptoms that he controls with
sleep hygiene techniques and persistence. A routine of
daily weighing, fluid restriction and monitoring of
dyspnea symptoms allows him to completely taper off
aldactone. He cuts out his morning coffee and bedtime
alcohol. He wears compression stockings and every
morning practices pelvic floor muscle exercises. Under
close surveillance from the cardiac team, he is able to
reduce his dose of furosemide to only 20 mg daily. He
only wakes up twice nightly to urinate and is able to
make it to the toilet on time. Three months later he no
longer leaks, is no longer depressed and has resumed
playing golf with his friends.
6 Conclusion
Up to 50 % of heart failure patients suffer from lower
urinary tract symptoms. Urinary frequency, urgency and
incontinence are extremely bothersome, while nocturnal
symptoms may disrupt sleep and quality of life. Healthcare
practitioners should be aware that medications used to treat
heart failure may indirectly provoke or exacerbate urinary
symptoms, and that tapering diuretics and switching ACE
inhibitors for ARBs are reasonable management approa-
ches. Therapeutic competition may occur as the dose of
diuretic is reduced, or new medication is added to treat
urinary symptoms. Judicious use of medication, combined
with patient collaboration for heart failure and lower uri-
nary symptom self-management are likely the best thera-
peutic approaches for improving outcomes for these
challenging co-morbid conditions.
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